S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Buy THIS stock before Taiwan is attacked (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
3 Free Stock Picks per Day (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Buy THIS stock before Taiwan is attacked (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
3 Free Stock Picks per Day (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Buy THIS stock before Taiwan is attacked (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
3 Free Stock Picks per Day (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
3 Free Stock Picks per Day (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Buy THIS stock before Taiwan is attacked (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
3 Free Stock Picks per Day (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
NASDAQ:EFTR

eFFECTOR Therapeutics (EFTR) Stock Forecast, Price & News

$0.66
+0.13 (+24.53%)
(As of 05/26/2023 ET)
Compare
Today's Range
$0.57
$0.74
50-Day Range
$0.35
$0.77
52-Week Range
$0.34
$2.97
Volume
32.96 million shs
Average Volume
512,279 shs
Market Capitalization
$27.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

eFFECTOR Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
581.8% Upside
$4.50 Price Target
Short Interest
Healthy
0.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.49mentions of eFFECTOR Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.74) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

289th out of 1,018 stocks

Pharmaceutical Preparations Industry

119th out of 498 stocks


EFTR stock logo

About eFFECTOR Therapeutics (NASDAQ:EFTR) Stock

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

Receive EFTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EFTR Stock News Headlines

"Chilling War Games Show US Forces Crushed" – FOX NEWS
=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
eFFECTOR Therapeutics (EFTR) Gets a Buy from Mizuho Securities
"Chilling War Games Show US Forces Crushed" – FOX NEWS
=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
eFFECTOR Therapeutics (EFTR) Receives a Buy from Mizuho Securities
See More Headlines
Receive EFTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EFTR Company Calendar

Last Earnings
3/08/2023
Today
5/27/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EFTR
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+581.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-22,670,000.00
Pretax Margin
-1,006.42%

Debt

Sales & Book Value

Annual Sales
$3.55 million
Book Value
($0.11) per share

Miscellaneous

Free Float
38,839,000
Market Cap
$27.98 million
Optionable
Not Optionable
Beta
0.36

Key Executives

  • Dr. Stephen T. Worland Ph.D. (Age 65)
    CEO, Pres & Director
    Comp: $753.39k
  • Mr. Michael Byrnes M.B.A. (Age 46)
    Chief Financial Officer
    Comp: $554.44k
  • Dr. Siegfried Reich Ph.D. (Age 63)
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Davide Ruggero Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Kevan M. Shokat Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Douglas Warner M.D.
    Chief Medical Officer
  • Dr. Mayank J. Gandhi M.D. (Age 45)
    Chief Bus. Officer













EFTR Stock - Frequently Asked Questions

Should I buy or sell eFFECTOR Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for eFFECTOR Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EFTR shares.
View EFTR analyst ratings
or view top-rated stocks.

What is eFFECTOR Therapeutics' stock price forecast for 2023?

3 equities research analysts have issued 12-month price targets for eFFECTOR Therapeutics' stock. Their EFTR share price forecasts range from $2.00 to $7.00. On average, they expect the company's share price to reach $4.50 in the next year. This suggests a possible upside of 581.8% from the stock's current price.
View analysts price targets for EFTR
or view top-rated stocks among Wall Street analysts.

How have EFTR shares performed in 2023?

eFFECTOR Therapeutics' stock was trading at $0.4276 at the start of the year. Since then, EFTR shares have increased by 54.3% and is now trading at $0.66.
View the best growth stocks for 2023 here
.

Are investors shorting eFFECTOR Therapeutics?

eFFECTOR Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 77,200 shares, a drop of 12.6% from the April 30th total of 88,300 shares. Based on an average daily volume of 209,200 shares, the short-interest ratio is presently 0.4 days. Currently, 0.4% of the company's shares are short sold.
View eFFECTOR Therapeutics' Short Interest
.

When is eFFECTOR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our EFTR earnings forecast
.

How were eFFECTOR Therapeutics' earnings last quarter?

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) issued its quarterly earnings data on Wednesday, March, 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.04. The business had revenue of $0.67 million for the quarter.

What is eFFECTOR Therapeutics' stock symbol?

eFFECTOR Therapeutics trades on the NASDAQ under the ticker symbol "EFTR."

Who are eFFECTOR Therapeutics' major shareholders?

eFFECTOR Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Carlyle Group Inc. (11.37%), Sea Otter Advisors LLC (0.62%) and Renaissance Technologies LLC (0.34%). Insiders that own company stock include Brian M Jr Gallagher, Christopher B Ehrlich, Jonathan D Root, Michael Byrnes, Presidio Management Group X Ll and Stephen T Worland.
View institutional ownership trends
.

How do I buy shares of eFFECTOR Therapeutics?

Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is eFFECTOR Therapeutics' stock price today?

One share of EFTR stock can currently be purchased for approximately $0.66.

How much money does eFFECTOR Therapeutics make?

eFFECTOR Therapeutics (NASDAQ:EFTR) has a market capitalization of $27.98 million and generates $3.55 million in revenue each year. The company earns $-22,670,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

How can I contact eFFECTOR Therapeutics?

eFFECTOR Therapeutics' mailing address is 200 CLARENDON STREET 51ST FLOOR, BOSTON MA, 02116. The official website for the company is www.locustwalkacquisitioncorp.com. The company can be reached via phone at 858-925-8215.

This page (NASDAQ:EFTR) was last updated on 5/27/2023 by MarketBeat.com Staff

My Account -